Abeona Grants Restricted Stock to Two New Hires

Abeona Therapeutics approved restricted stock awards for two non-executive employees under a Nasdaq inducement exemption.

Updated on Nov. 2, 2026 in Public Companies

Abeona Grants Restricted Stock to Two New Hires

Abeona Therapeutics granted restricted stock equity awards to two new non-executive employees on October 31, 2026. The awards cover up to 5,100 restricted shares of common stock and were granted as a material inducement to employment.

Why it matters

The awards were approved under Nasdaq Listing Rule 5635(c)(4), which permits equity grants to new hires outside a shareholder-approved plan. The vesting schedule ties each employee's stake to continued employment over three years.

Up to 5,100 restricted shares of Abeona common stock were granted in aggregate, with one-third vesting on each anniversary of the October 31, 2026 Grant Date. The filing does not break out the share count per employee, and the individual allocations remain unspecified.

The players

Abeona Therapeutics

Abeona Therapeutics is a Cleveland-based, Nasdaq-listed biotechnology company developing gene and cell therapies for rare genetic diseases.

The details

The Compensation Committee of Abeona's Board of Directors approved the restricted stock awards for the two individuals. Each employee's shares are fully vested on the third anniversary of the Grant Date, provided they remain employed with Abeona on each vesting date.

October 31, 2026: Compensation Committee granted the restricted stock awards to two employees.
November 2, 2026: Abeona announced the employee inducement equity awards.
Third anniversary of the Grant Date: restricted shares fully vest for each employee.

Market Landscape

Nasdaq Listing Rule 5635(c)(4) lets listed companies grant equity as an inducement to new hires without shareholder approval, a route Abeona used for these two awards. The grants reflect how public biotechnology companies compete for talent using equity rather than cash compensation.

For Abeona shareholders, the awards add up to 5,100 shares of potential dilution that vest over three years. Employees who remain with the company will receive their full share allotment only by the third anniversary of the grant.

The takeaway

Equity inducement grants are a common tool for biotech firms hiring talent, and their multi-year vesting schedules reward staying with the company. Investors tracking dilution can review the vesting terms to estimate the share impact over time.